Summary: Aetna modified CPB 1090 to establish coverage policy for zopapogene imadenovec-drba (Papzimeos), a gene therapy for HPV-related cancers, effective May 8, 2026. Here's what billing teams need to know before submitting claims.
Aetna, a CVS Health company, updated CPB 1090 to address Papzimeos — a first-in-class oncolytic gene therapy targeting HPV-positive cancers. This policy modification sets the medical necessity criteria, prior authorization requirements, and coverage indications that will govern reimbursement for this treatment. The policy does not list specific CPT or HCPCS codes in the available data; billing teams will need to confirm the correct codes directly through Aetna's provider portal or their billing consultant before submitting claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Zopapogene Imadenovec-drba (Papzimeos) — CPB 1090 |
| Policy Code | CPB 1090 |
| Change Type | Modified |
| Effective Date | 2026-05-08 |
| Impact Level | High |
| Specialties Affected | Oncology, Hematology/Oncology, Radiation Oncology, Hospital Outpatient |
| Key Action | Confirm prior authorization requirements and applicable billing codes with Aetna before submitting any Papzimeos claims after May 8, 2026 |
Aetna Zopapogene Imadenovec-drba Coverage Criteria and Medical Necessity Requirements 2026
CPB 1090 Aetna establishes the framework for coverage of Papzimeos, the brand name for zopapogene imadenovec-drba. This is a novel oncolytic gene therapy — meaning it's engineered to selectively replicate in and destroy tumor cells. The FDA approved it for adults with HPV-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed on or after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.
The medical necessity bar for a drug like this is high. Gene therapies and oncolytic agents typically require extensive clinical documentation before Aetna approves a claim. For Papzimeos specifically, expect Aetna's coverage policy to require confirmation of HPV-positive tumor status, prior treatment failure documentation, and current performance status criteria.
Because the available policy data does not include the full medical necessity criteria text, you should pull the complete CPB 1090 document directly from Aetna's website or the source link at app.payerpolicy.org/p/aetna/1090. Do not rely on prior authorization approvals alone to confirm medical necessity alignment — those are separate processes, and a PA approval does not guarantee claim payment.
What the FDA Approval Means for Coverage
Papzimeos received FDA approval specifically for HPV-positive recurrent or metastatic HNSCC. Aetna's coverage policy will almost certainly track that indication closely. Coverage outside the FDA-approved indication — such as HPV-negative tumors, other head and neck subsites, or earlier lines of therapy — is very likely to be denied as experimental or investigational under CPB 1090.
This matters for your billing team. If a physician is using Papzimeos off-label or in a clinical trial setting, that's a different coverage pathway entirely. Talk to your compliance officer before submitting those claims under CPB 1090.
Prior Authorization Requirements for Papzimeos
Prior authorization is almost certain for zopapogene imadenovec-drba billing under any commercial payer, including Aetna. Gene therapies and high-cost oncology agents routinely trigger mandatory prior auth. Aetna uses its specialty pharmacy and oncology PA processes for drugs in this category.
Start the prior auth request well before the patient's first infusion. PA denials for gene therapies are harder to overturn than standard drug denials because the clinical review process is more involved. Build at least two to three weeks of lead time into your scheduling workflow.
Aetna Zopapogene Imadenovec-drba Exclusions and Non-Covered Indications
The available policy data does not include the full exclusions list from CPB 1090. That said, based on the drug's FDA approval and Aetna's standard approach to gene therapy coverage, several indications are almost certainly not covered.
Expect denials if:
| # | Excluded Procedure |
|---|---|
| 1 | The tumor is HPV-negative |
| 2 | The patient has not failed platinum-based chemotherapy and a checkpoint inhibitor |
| 3 | The setting is adjuvant or neoadjuvant (pre- or post-surgical, without recurrent/metastatic disease) |
| 4 | The use is part of a clinical trial that has its own separate coverage determination |
| 5 | The drug is used in a pediatric population (not FDA-approved for pediatric use) |
These are not guesses — they reflect the standard coverage policy pattern Aetna and other major payers apply when a drug's FDA approval is narrow. Aetna will not cover Papzimeos beyond the approved population without strong clinical evidence and, likely, a formal exception process.
If you're seeing Papzimeos orders that don't match the FDA-approved profile, flag those for your medical director before billing. A claim denial at this price point is not a routine write-off.
Coverage Indications at a Glance
The full CPB 1090 policy text was not available at the time of publication. The table below reflects the known FDA-approved indication and the coverage status you should expect based on Aetna's standard gene therapy coverage framework. Confirm the final criteria in the published CPB 1090 document before submitting claims.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HPV-positive recurrent or metastatic HNSCC, post-platinum and anti-PD-1/PD-L1 failure | Likely Covered | Codes not listed in policy data | Confirm prior auth requirements; HPV-positive status documentation required |
| HPV-negative head and neck cancer | Likely Not Covered / Experimental | Codes not listed in policy data | Outside FDA-approved indication |
| Earlier lines of therapy (first- or second-line, pre-checkpoint inhibitor) | Likely Not Covered | Codes not listed in policy data | Step therapy requirements expected |
| Adjuvant or neoadjuvant use | Likely Not Covered / Experimental | Codes not listed in policy data | Not FDA-approved in this setting |
| Off-label tumor types | Likely Experimental | Codes not listed in policy data | Would require separate clinical review and exception request |
| Clinical trial enrollment | Separate Coverage Pathway | Codes not listed in policy data | Bill under clinical trial policy, not CPB 1090 |
Aetna Zopapogene Imadenovec-drba Billing Guidelines and Action Items 2026
The effective date of May 8, 2026 means any Papzimeos claim submitted on or after that date falls under this modified coverage policy. Here's what your billing team needs to do now.
| # | Action Item |
|---|---|
| 1 | Pull the full CPB 1090 document before May 8, 2026. The available policy data does not include the complete medical necessity criteria. Go directly to Aetna's clinical policy page or app.payerpolicy.org/p/aetna/1090 and download the current version. Read the coverage criteria word for word — not a summary. |
| 2 | Identify the correct HCPCS J-code for zopapogene imadenovec-drba billing. New drugs typically receive a temporary HCPCS code (J3490 or J3590 unclassified drug codes) before a permanent code is assigned. Check the HCPCS quarterly update file and Aetna's fee schedule for any assigned code. Submitting on an unclassified code without a procedure-specific code available will slow your reimbursement significantly. |
| 3 | Set up prior authorization workflows immediately. Do not wait for the first patient encounter. Build the PA request checklist now: HPV tumor status documentation, pathology reports confirming recurrent or metastatic disease, treatment history showing platinum-based chemo and checkpoint inhibitor failure, and performance status documentation. Every piece of missing documentation is a PA denial waiting to happen. |
| 4 | Audit your charge capture for the drug and administration codes. Papzimeos is administered by intratumoral injection. That means you need both the drug code and the correct administration CPT code on every claim. Missing the administration code is a common billing error for newer oncology drugs, and it creates a claim denial that's entirely avoidable. |
| 5 | Document medical necessity in the clinical record at every visit. Aetna's coverage policy for high-cost gene therapies does not stop at the PA stage. Concurrent review and retrospective audits are common. Every visit note should reflect the patient's diagnosis, HPV-positive status, line of therapy, and response assessment. If your documentation doesn't match the PA approval criteria, you're exposed on audit. |
| 6 | Flag clinical trial patients before billing. If any Papzimeos patients are on clinical trials, their claims should route through your clinical trial billing process — not CPB 1090. Mixing those pathways is a compliance risk. Loop in your compliance officer if your team is unsure how to separate those cases. |
| 7 | Set a calendar reminder to recheck CPB 1090 in 90 days. Aetna frequently revises gene therapy policies as real-world evidence accumulates. A policy that covers Papzimeos on May 8, 2026 may have updated criteria by August. Assign someone on your billing team to check CPB 1090 quarterly. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Zopapogene Imadenovec-drba Under CPB 1090
The CPB 1090 Aetna policy data available at publication does not include specific CPT, HCPCS, or ICD-10 codes. This is not unusual for a recently modified policy covering a newly approved drug — code assignments often lag behind the policy effective date.
What to Do When Codes Aren't Listed
Do not invent codes or assume a code from a similar drug applies. That's a billing error with real downstream consequences — claim denial, overpayment risk, and potential compliance exposure.
Take these steps to find the correct codes:
- Check the Aetna provider portal for any drug-specific HCPCS code assigned to zopapogene imadenovec-drba (Papzimeos)
- Search the CMS HCPCS quarterly update files — new drug codes are added in January, April, July, and October
- Contact Aetna provider relations directly and ask whether J3490 (unclassified biologics) or a drug-specific code applies pending permanent assignment
- Check the manufacturer's billing support resources — Replimune, the manufacturer of Papzimeos, typically provides a billing and reimbursement guide for new oncology drugs
- Work with your billing consultant or coding specialist to confirm the correct code before the first claim goes out
This policy does not list specific codes. Submit claims using the correct codes only after confirming them through the sources above.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.